Shanghai Yi Tai Pharmaceutical Technology Co. Ltd. plans to establish a fully integrated biotechnology development base and an international research and development center in Nuclear Medicine.

       Adhering to the “Longcheng Talent” program, it has established a pharmaceutical R&D platform， introduced domestic and international medical high technology talents to jointly develop these technologies for commercialization. Supported by this program and both National and international research organizations, we are going to establish an “International Center for research and development of radio-pharmaceuticals” and a radiopharmaceuticals production base. Short half-life radioactive nuclides can be taken as “warhead”, using the biological target-specific drugs already on the market or under development, to develop “biological missiles” radiopharmaceuticals.

       To meet the Company's goals and commercialization objectives of the local government, the company has reached intent with the Shanghai International Medical Zone to build a comprehensive biotechnology research and development center and the radiopharmaceuticals R&D and production base.